Literature DB >> 19072487

Management of endometrial cancer.

Wiley Fowler1, David Mutch.   

Abstract

Endometrial cancer is the fourth most common malignancy diagnosed in US women. Although most cases present in early stages and respond well to surgical staging with appropriately administered adjuvant radiation, the prognosis for advanced endometrial cancers is comparatively poor. Currently available treatments for advanced and recurrent metastatic endometrial cancer have significant toxicities, and are given to a population that is usually elderly with multiple other medical comorbidities. This article examines the pathogenesis of endometrial cancer as well as its diagnosis and management.

Entities:  

Mesh:

Year:  2008        PMID: 19072487     DOI: 10.2217/17455057.4.5.479

Source DB:  PubMed          Journal:  Womens Health (Lond)        ISSN: 1745-5057


  3 in total

1.  Extracellular matrix metalloproteinase inducer and matrix metalloproteinase-2 overexpression is associated with loss of hormone receptor expression and poor prognosis in endometrial cancer.

Authors:  Yuan Yuan; Ning Shen; Shu-Yan Yang; Ling Zhao; Yong-Mei Guan
Journal:  Oncol Lett       Date:  2015-05-06       Impact factor: 2.967

2.  Overexpression of HABP1 correlated with clinicopathological characteristics and unfavorable prognosis in endometrial cancer.

Authors:  Jia Zhao; Tianbo Liu; Ge Yu; Jing Wang
Journal:  Tumour Biol       Date:  2014-10-30

3.  Association between IL-6 Gene (-174 & -572 G/C) Polymorphisms and Endometrial Adenocarcinoma Risk.

Authors:  Hai-Ying Wang; Jin-Jun Zhang; Xiang-Yu Zheng; Jian-Hua Liu; Yong-Wei Li
Journal:  Pathol Oncol Res       Date:  2016-05-19       Impact factor: 3.201

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.